The state of MIIND

MIIND (Multiple Interacting Instantiations of Neural Dynamics) is a highly modular multi-level C++ framework, that aims to shorten the development time for models in Cognitive Neuroscience (CNS). It offers reusable code modules (libraries of classes and functions) aimed at solving problems that occur repeatedly in modelling, but tries not to impose a specific modelling philosophy or methodology. At the lowest level, it offers support for the implementation of sparse networks. For example, the library SparseImplementationLib supports sparse random networks and the library LayerMappingLib can be used for sparse regular networks of filter-like operators. The library DynamicLib, which builds on top of the library SparseImplementationLib, offers a generic framework for simulating network processes. Presently, several specific network process implementations are provided in MIIND: the Wilson–Cowan and Ornstein–Uhlenbeck type, and population density techniques for leaky-integrate-and-fire neurons driven by Poisson input. A design principle of MIIND is to support detailing: the refinement of an originally simple model into a form where more biological detail is included. Another design principle is extensibility: the reuse of an existing model in a larger, more extended one. One of the main uses of MIIND so far has been the instantiation of neural models of visual attention. Recently, we have added a library for implementing biologically-inspired models of artificial vision, such as HMAX and recent successors. In the long run we hope to be able to apply suitably adapted neuronal mechanisms of attention to these artificial models

OSD2F: An Open-Source Data Donation Framework

The digital traces that people leave through their use of various online platforms provide tremendous opportunities for studying human behavior. However, the collection of these data is hampered by legal, ethical, and technical challenges. We present a framework and tool for collecting these data through a data donation platform where consenting participants can securely submit their digital traces. This approach leverages recent developments in data rights that have given people more control over their own data, such as legislation that now mandates companies to make digital trace data available on request in a machine-readable format. By transparently requesting access to specific parts of this data for clearly communicated academic purposes, the data ownership and privacy of participants is respected, and researchers are less dependent on commercial organizations that store this data in proprietary archives. In this paper we outline the general design principles, the current state of the tool, and future development goals

Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.

Despite the advances in pre-, peri- and post-operative medical care of colorectal carcinoma patients, the prognosis has improved only marginally over recent decades. Thus, additional prognostic indicators would be of great clinical value to select patients for adjuvant therapy. In previous studies we found that colorectal carcinomas have a marked increase of the urokinase-type of plasminogen activator (u-PA), and the inhibitors PAI-1 and PAI-2, whereas the tissue-type plasminogen activator (t-PA) is found to be decreased in comparison with adjacent normal mucosa. In the present study we evaluated the prognostic value of several plasminogen activation parameters, determined in both normal and carcinomatous tissue from colorectal resection specimens, for overall survival of 136 Dukes' stage B and C colorectal cancer patients, in relation to major clinicopathological parameters. Uni- and multivariate analyses indicated that a high PAI-2 antigen level in carcinoma, a low t-PA activity and antigen level and a high u-PA/t-PA antigen ratio in adjacent normal mucosa are significantly associated with a poor overall survival. A high ratio of u-PA antigen in the carcinomas and t-PA antigen in normal mucosa, i.e. u-PA(C)/t-PA(N), was found to be predictive of a poor overall survival as well. All these parameters were found to be prognostically independent of the clinicopathological parameters. Multivariate analysis of combinations of these prognostically significant plasminogen activation parameters revealed that they are important independent prognostic indicators and have in fact a better prognostic value than their separate components. Based on these combined parameters, subgroups of patients with Dukes' stage B and C colorectal cancer could be identified as having either a high or a low risk regarding overall survival. In conclusion, these findings emphasize the relevance of the intestinal plasminogen activation system for survival prognosis of patients with colorectal cancer and, in the future, might constitute a patient selection criterion for adjuvant therapy

Ferric carboxymaltose versus ferrous fumarate in anemic children with inflammatory bowel disease:the POPEYE randomized controlled clinical trial

OBJECTIVE: To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness in anemic children with inflammatory bowel disease (IBD).STUDY DESIGN: We conducted a clinical trial at 11 centers. Children aged 8 to 18 with IBD and anemia (defined as hemoglobin (Hb) z-score &lt; -2) were randomly assigned to a single IV dose of ferric carboxymaltose or 12 weeks of oral ferrous fumarate. Primary endpoint was the change in 6-minute walking distance (6MWD) from baseline, expressed as z-score. Secondary outcome was a change in Hb z-score from baseline.RESULTS: We randomized 64 patients (33 IV iron; 31 oral iron) and followed them for 6 months. One month after the start of iron therapy, the 6MWD z-score of patients in the IV group had increased by 0.71 compared with -0.11 in the oral group (P=0.01). At 3- and 6-months follow-up, no significant differences in 6MWD z-scores were observed. Hb z-scores gradually increased in both groups and the rate of increase was not different between groups at 1, 3 and 6 months after initiation of iron therapy (overall P=0.97).CONCLUSION: In this trial involving anemic children with IBD, a single dose of IV ferric carboxymaltose was superior to oral ferrous fumarate with respect to quick improvement of physical fitness. At 3 and 6 months after initiation of therapy, no differences were discovered between oral or IV therapy. The increase of Hb over time was comparable in both treatment groups.TRIAL REGISTRATION: NTR4487 [Netherlands Trial Registry].</p